Back to top
more

Orthofix Medical (OFIX)

(Delayed Data from NSDQ)

$18.40 USD

18.40
545,035

+0.69 (3.90%)

Updated Nov 6, 2024 03:59 PM ET

After-Market: $18.40 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (89 out of 251)

Industry: Medical - Instruments

Zacks News

Orthofix (OFIX) Stock Declines 13% on '18 Earnings View Cut

Despite the bottom line of Orthofix (OFIX) betters estimates, the company's shares drop due to trimmed 2018 earnings outlook.

    FDA Nod for Orthofix's G-Beam to Boost Extremity Fixation SBU

    Orthofix's (OFIX) latest receipt of FDA approval expected to enhance the Extremity Fixation portfolio.

      What's Driving Orthofix International to a New 52-Week High

      Orthofix International is (OFIX) strong on recent buyouts as well as the FDA approval.

        Orthopedic Device Market Gains Momentum: 3 Stocks in Focus

        The orthopedics market holds immense potential for investors who are keen on the healthcare space for long-term gains.

          Orthofix to Buy Spinal Kinetics, Widens Spine Fixation Suite

          Orthofix's (OFIX) latest deal to boost Spine Fixation portfolio and strengthen hold in the high-potential artificial disc market buoys optimism.

            Orthofix PhysioStim's FDA Nod and CE Mark Boosts Prospects

            Orthofix (OFIX) vouches for PhysioStim's efficiency, claiming the devices to lead the U.S. market of prescribed bone growth stimulators combined with spinal fusion stimulators.

              Orthofix (OFIX) Earnings & Revenues Beat Estimates in Q4

              Orthofix (OFIX) launches 20 products in 2018 and even schedules 17 more to be unveiled this year. Also, a strong full-year guidance bodes well for the company's better prospects.

                MedTech Industry Outlook - October 2017

                The Trump administration has not come up with any concrete plan to replace the MedTech tax as of yet.

                  Stryker (SYK) to Gain From Solid Portfolio and Acquisitions

                  Stryker's (SYK) diverse portfolio and accretive acquisitions is instrumental in aiding the company's top-line growth.

                    Fresenius Medical (FMS) Well Poised on Growth Strategy 2020

                    Fresenius Medical (FMS) is banking on its Growth Strategy 2020 plan for gaining market traction in the future. However, lackluster performance in the bourse is a concern.

                      Boston Scientific Grows on New Products, Currency Woe Ails

                      Boston Scientific (BSX) is gaining traction on product launch and accretive acquisitions. Yet an unfavorable currency movement is a major dampener.

                        DaVita Banks on Acquisitions, Escalating Expenses a Concern

                        DaVita HealthCare Partners' (DVA) focus on acquisitions will boost the company's expansion. However, rising expenses remains headwind.

                          Hurricane Maria to Hurt Medtronic in Q2, FY18 View Intact

                          Medtronic (MDT) expects normal manufacturing process in Puerto Rico to resume in full force in the coming weeks with considerable repairing done in the aftermath of Hurricane Maria.

                            Integra's (IART) Revize/Revize-X Boosts Tissue Technology Arm

                            Integra (IART) widens its tissue technology segment with the launch of Revize/Revize-X Collagen Matrix for plastic and reconstructive surgery.

                              Abbott (ABT) Hits a 52-Week High: What's Driving the Stock?

                              The market is upbeat about Abbott's (ABT) recent FDA approvals and buyouts.

                                QIAGEN's QFT-Plus Launch to Boost Molecular Diagnostics Arm

                                QIAGEN (QGEN) strengthens its highest revenue grossing segment with the launch of QuantiFERON-TB Gold Plus in the United States.

                                  Hologic's Panther Fusion Flu A/B/RSV Assay Gets FDA Approval

                                  Hologic's (HOLX) receipt of FDA approval for Panther Fusion Flu A/B/RSV assay running on the new Panther Fusion system is likely to boost its Diagnostic segment.

                                    Masimo (MASI) Launches Trace Data and Reporting Tool in US

                                    Masimo's (MASI) launch of Trace in the United States will aid the company in capturing the growing patient data visualization market.

                                      Genomic Health's Cost Pressure Mounts, Cancer Tests Strong

                                      Concerns related to Genomic Health's (GHDX) strong dependence on breast cancer tests still linger. Also, higher production cost and expenses continue to weigh heavily on the company's margins.

                                        Integra Rides High on Product Launches, Competition Rife

                                        Integra LifeSciences' (IART) latest launch of new sizes of SurgiMend and PriMatrix and Omnigraft as well as continued growth in private label products is encouraging.

                                          Henry Schein to Offer CAS' Fully-Automated Cognivue Device

                                          Henry Schein (HSIC) is consistently working toward boosting its Medical segment.

                                            Hill-Rom (HRC) Rides on Product Launches, Competition Rife

                                            Hill-Rom (HRC) focuses on product innovation through research and development. Its product launches slated for the fourth quarter are boosting investors' confidence.

                                              Integra LifeSciences' SurgiMend PRS Meshed Boosts ADM Line

                                              Advancing its portfolio of acellular dermal tissue matrix for plastic and reconstructive surgery, including breast reconstruction, Integra LifeSciences (IART) launched SurgiMend PRS Meshed in Europe.

                                                Boston Scientific's Apama Deal to Boost Electrophysiology Arm

                                                Boston Scientific's (BSX) Apama Medical addition is expected to strengthen its suite of arrhythmia solutions under the Electrophysiology sub-segment.

                                                  Capricor Therapeutics (CAPR) Looks Good: Stock Adds 13.9% in Session

                                                  Capricor Therapeutics (CAPR) was a big mover last session, as the company saw its shares rise almost 14% on the day amid huge volumes.